3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
122
pembrolizumab
118
Magnetic Resonance Spectroscopy
107
Carboplatin
86
Cyclophosphamide
75
Biopsy
68
Cisplatin
63
Paclitaxel
58
Bevacizumab
56
Gemcitabine
49
Nivolumab
47
fludarabine
44
Dexamethasone
39
Rituximab
38
Pemetrexed
38
Fluorouracil
37
atezolizumab
36
Docetaxel
36
Doxorubicin
34
Radiotherapy
33
Leucovorin
33
venetoclax
31
Oxaliplatin
30
Capecitabine
30
Temozolomide
28
Prednisone
28
Standard of Care
27
Radiation
27
Letrozole
27
Cetuximab
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Serotonin 5-HT3 Receptor Antagonists
×
30 days
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled